Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice ...

When Nicole Stovall stepped into her new role as Chief Diversity Officer at Merck, it wasn’t just another career milestone—it was the manifestation of years of purpose, persistence, and faith […] ...

Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Early and sustained ctDNA clearance in early breast cancer treated with neoadjuvant HER2-targeted therapy tracks closely with pathologic complete response to treatment and 3-year outcomes.

Ringside’s phase 3 findings reveal the potential varegacestat has to deliver “best-in-class results in a convenient, ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day on December 9th, 2025, at the Harvard Club in New York City. The morning presentations ...

In the big picture, matched sibling donor transplants remain the standard of care, Boelens said. But gene therapy is ...

Findings from a phase 3 study provided additional evidence that the first pneumococcal vaccine made specifically for adults ...

Option traders moderately bearish in Merck (MRK), with shares down 16c near $99.29. Options volume roughly in line with average with 32k contracts ...

Federal officials say the FDA is reviewing reports of possible deaths in adults and children following COVID-19 vaccination.

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...